| Literature DB >> 33321963 |
Paola Peinado1,2, Alvaro Andrades1,2, Marta Cuadros2,3,4, Maria Isabel Rodriguez2,3,4, Isabel F Coira5,6, Daniel J Garcia2,4, Juan Carlos Álvarez-Perez1,2, Carlos Baliñas-Gavira1,2, Alberto M Arenas1,2, Juan Rodrigo Patiño-Mercau1,2, Juan Sanjuan-Hidalgo2, Octavio A Romero7, Luis M Montuenga8,9, Julian Carretero10, Montserrat Sanchez-Cespedes7, Pedro P Medina1,2,3.
Abstract
Mammalian SWI/SNF (SWitch/Sucrose Non-Fermentable) complexes are ATP-dependent chromatin remodelers whose subunits have emerged among the most frequently mutated genes in cancer. Studying SWI/SNF function in cancer cell line models has unveiled vulnerabilities in SWI/SNF-mutant tumors that can lead to the discovery of new therapeutic drugs. However, choosing an appropriate cancer cell line model for SWI/SNF functional studies can be challenging because SWI/SNF subunits are frequently altered in cancer by various mechanisms, including genetic alterations and post-transcriptional mechanisms. In this work, we combined genomic, transcriptomic, and proteomic approaches to study the mutational status and the expression levels of the SWI/SNF subunits in a panel of 38 lung adenocarcinoma (LUAD) cell lines. We found that the SWI/SNF complex was mutated in more than 76% of our LUAD cell lines and there was a high variability in the expression of the different SWI/SNF subunits. These results underline the importance of the SWI/SNF complex as a tumor suppressor in LUAD and the difficulties in defining altered and unaltered cell models for the SWI/SNF complex. These findings will assist researchers in choosing the most suitable cellular models for their studies of SWI/SNF to bring all of its potential to the development of novel therapeutic applications.Entities:
Keywords: SWI/SNF complex; cell models; epigenetics; lung adenocarcinoma; lung cancer; multi-omics
Year: 2020 PMID: 33321963 PMCID: PMC7763689 DOI: 10.3390/cancers12123712
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639